Commentary on "Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data"
- PMID: 28751507
- PMCID: PMC5599207
- DOI: 10.1634/theoncologist.2017-0232
Commentary on "Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data"
Abstract
Assessing a recent retrospective analysis, conclusions differ on whether a weekly regimen could be adopted as a reasonable standard of care option. This commentary questions how study results are interpreted, what considerations are most important for patient care, and where efforts should be focused for the next generation of trials.
Comment on
-
Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.Oncologist. 2017 Sep;22(9):1056-1066. doi: 10.1634/theoncologist.2017-0015. Epub 2017 May 22. Oncologist. 2017. PMID: 28533474 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
